For US residents only.
Because other treatment options have not kept your cancer in remission, the goal of KYMRIAH® (tisagenlecleucel) therapy is long-term remission of your cancer. Studies first began in 2012, and Novartis has since treated many patients with CAR-T therapy. Since 2015, KYMRIAH has been studied in a global clinical trial of children and young adults with relapsed or refractory B-cell ALL, with many achieving an early and lasting remission. Click each button below to see the results of the KYMRIAH clinical trial. While many patients have been successfully treated with KYMRIAH, not all patients will respond the same way.
52 of 63 children and young adults treated with KYMRIAH had their cancer go into remission. For nearly everyone, remission happened between 26 and 31 days after KYMRIAH infusion.
All 52 of those in remission after KYMRIAH had undetectable levels of cancer left in their bone marrow (MRD–).*
*Doctors can use highly sensitive tests to look for traces of cancer in bone marrow called minimal residual disease or MRD. These tests give a very precise measure of remission that may indicate to your treatment team how well KYMRIAH is working.
46 of the 52 children and young adults who went into remission after treatment with KYMRIAH did not need an allogeneic transplant.